AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
streptomycin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| antibiotics, produced by Streptomyces strains | 2481 | 57-92-1 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
An antibiotic produced by the soil actinomycete Streptomyces griseus. It acts by inhibiting the initiation and elongation processes during protein synthesis.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 1 | g | P |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 3 | Benet LZ, Broccatelli F, Oprea TI |
| S (Water solubility) | 20 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
| EoM (Fraction excreted unchanged in urine) | 55 % | Benet LZ, Broccatelli F, Oprea TI |
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 34.39 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
| BA (Bioavailability) | 1 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
| Vd (Volume of distribution) | 0.34 L/kg | Lombardo F, Berellini G, Obach RS |
| CL (Clearance) | 0.78 mL/min/kg | Lombardo F, Berellini G, Obach RS |
| fu (Fraction unbound in plasma) | 0.65 % | Lombardo F, Berellini G, Obach RS |
| t_half (Half-life) | 4.30 hours | Lombardo F, Berellini G, Obach RS |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | ACVR2B,AXL,BRAF,CAMK2D,CDK4,CDK5,CDK9,DDR1,DYRK1B,EIF2AK3,ERBB2,GRK2,ITK,MAP2K6,MAP3K21,MAPK10,MAPK7,NTRK1,NTRK2,PDK2,PDK4,PRKDC,TEK,TGFBR1,ZAP70 | 25 | |||
| kinase-selectivity-class | CHUK,MAP2K6,PDK1 | 3 | |||
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Feb. 18, 1946 | FDA | PFIZER |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Vaginal flatulence | 76.77 | 50.43 | 20 | 1135 | 12618 | 90614674 |
| Proctitis | 73.03 | 50.43 | 20 | 1135 | 15239 | 90612053 |
| Drug reaction with eosinophilia and systemic symptoms | 71.46 | 50.43 | 25 | 1130 | 42733 | 90584559 |
| Female genital tract fistula | 69.91 | 50.43 | 20 | 1135 | 17848 | 90609444 |
| Radiculopathy | 69.21 | 50.43 | 20 | 1135 | 18485 | 90608807 |
| Vaginal discharge | 68.22 | 50.43 | 20 | 1135 | 19444 | 90607848 |
| Chronic sinusitis | 64.25 | 50.43 | 20 | 1135 | 23782 | 90603510 |
| Oral candidiasis | 60.25 | 50.43 | 21 | 1134 | 35434 | 90591858 |
| Paraesthesia oral | 58.64 | 50.43 | 20 | 1135 | 31639 | 90595653 |
| Macular degeneration | 55.08 | 50.43 | 20 | 1135 | 37950 | 90589342 |
| Paradoxical drug reaction | 54.43 | 50.43 | 13 | 1142 | 5753 | 90621539 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Paradoxical drug reaction | 128.98 | 44.87 | 29 | 1114 | 4709 | 42615483 |
| Drug resistance | 124.09 | 44.87 | 43 | 1100 | 34205 | 42585987 |
| Tuberculoma of central nervous system | 77.07 | 44.87 | 12 | 1131 | 257 | 42619935 |
| Immune reconstitution inflammatory syndrome | 75.13 | 44.87 | 22 | 1121 | 10121 | 42610071 |
| Pathogen resistance | 68.23 | 44.87 | 21 | 1122 | 11429 | 42608763 |
| Immune reconstitution inflammatory syndrome associated tuberculosis | 67.84 | 44.87 | 12 | 1131 | 569 | 42619623 |
| Urinary tract inflammation | 63.21 | 44.87 | 10 | 1133 | 238 | 42619954 |
| Hepatitis cholestatic | 62.71 | 44.87 | 19 | 1124 | 9805 | 42610387 |
| Conductive deafness | 49.33 | 44.87 | 9 | 1134 | 508 | 42619684 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Paradoxical drug reaction | 177.43 | 43.98 | 41 | 2233 | 9776 | 110577249 |
| Drug resistance | 147.52 | 43.98 | 52 | 2222 | 56322 | 110530703 |
| Immune reconstitution inflammatory syndrome associated tuberculosis | 89.75 | 43.98 | 16 | 2258 | 1038 | 110585987 |
| Pathogen resistance | 85.54 | 43.98 | 26 | 2248 | 17646 | 110569379 |
| Tuberculoma of central nervous system | 84.14 | 43.98 | 14 | 2260 | 603 | 110586422 |
| Immune reconstitution inflammatory syndrome | 79.08 | 43.98 | 24 | 2250 | 16202 | 110570823 |
| Drug reaction with eosinophilia and systemic symptoms | 73.05 | 43.98 | 35 | 2239 | 82060 | 110504965 |
| Vaginal flatulence | 68.00 | 43.98 | 20 | 2254 | 12124 | 110574901 |
| Female genital tract fistula | 61.94 | 43.98 | 20 | 2254 | 16499 | 110570526 |
| Proctitis | 61.46 | 43.98 | 20 | 2254 | 16907 | 110570118 |
| Urinary tract inflammation | 61.11 | 43.98 | 10 | 2264 | 388 | 110586637 |
| Vaginal discharge | 60.35 | 43.98 | 20 | 2254 | 17888 | 110569137 |
| Radiculopathy | 58.84 | 43.98 | 20 | 2254 | 19316 | 110567709 |
| Macular degeneration | 56.62 | 43.98 | 20 | 2254 | 21639 | 110565386 |
| Conductive deafness | 56.36 | 43.98 | 9 | 2265 | 299 | 110586726 |
| Chronic sinusitis | 53.76 | 43.98 | 20 | 2254 | 25064 | 110561961 |
| Drug-induced liver injury | 52.65 | 43.98 | 32 | 2242 | 120035 | 110466990 |
| Oral candidiasis | 48.85 | 43.98 | 22 | 2252 | 44738 | 110542287 |
| Paraesthesia oral | 48.04 | 43.98 | 20 | 2254 | 33651 | 110553374 |
| Pyrexia | 46.46 | 43.98 | 73 | 2201 | 898192 | 109688833 |
| Hepatitis cholestatic | 45.07 | 43.98 | 16 | 2258 | 17550 | 110569475 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | A07AA04 | ALIMENTARY TRACT AND METABOLISM ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS INTESTINAL ANTIINFECTIVES Antibiotics |
| ATC | A07AA54 | ALIMENTARY TRACT AND METABOLISM ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS INTESTINAL ANTIINFECTIVES Antibiotics |
| ATC | J01GA01 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE AMINOGLYCOSIDE ANTIBACTERIALS Streptomycins |
| ATC | J04AM01 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIMYCOBACTERIALS DRUGS FOR TREATMENT OF TUBERCULOSIS Combinations of drugs for treatment of tuberculosis |
| FDA CS | M0000946 | Aminoglycosides |
| FDA EPC | N0000175477 | Aminoglycoside Antibacterial |
| FDA EPC | N0000175483 | Antimycobacterial |
| MeSH PA | D000890 | Anti-Infective Agents |
| MeSH PA | D000900 | Anti-Bacterial Agents |
| MeSH PA | D004791 | Enzyme Inhibitors |
| MeSH PA | D011500 | Protein Synthesis Inhibitors |
| CHEBI has role | CHEBI:33281 | antimicrobial agent |
| CHEBI has role | CHEBI:36043 | antimicrobial drug |
| CHEBI has role | CHEBI:36047 | antibacterial drug |
| CHEBI has role | CHEBI:48001 | protein synthesis inhibitor |
| CHEBI has role | CHEBI:76969 | bacterial metabolite |
| CHEBI has role | CHEBI:86328 | antifungal agrochemical |
Related Drugs by ATC class:
A07AA Antibiotics 12 drugs
J01GA Streptomycins 1 drug
J04AM Combinations of drugs for treatment of tuberculosis 11 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Tularemia | indication | 19265001 | |
| Acute tuberculosis | indication | 25629007 | |
| Granuloma inguinale | indication | 28867007 | DOID:9113 |
| Plague | indication | 58750007 | DOID:3482 |
| Klebsiella cystitis | indication | 60867007 | |
| Haemophilus influenzae pneumonia | indication | 70036007 | |
| Brucellosis | indication | 75702008 | DOID:11077 |
| Pulmonary tuberculosis | indication | 154283005 | DOID:2957 |
| Chancroid | indication | 266143009 | DOID:13778 |
| Escherichia coli urinary tract infection | indication | 301011002 | |
| Proteus urinary tract infection | indication | 301012009 | |
| Bacterial urinary infection | indication | 312124009 | |
| Aerobic Gram-Negative Bacteremia | indication | ||
| Synergy for Streptococcal Endocarditis | indication | ||
| Haemophilus Endocarditis | indication | ||
| Synergy for Enterococcal Endocarditis | indication | ||
| Enterococcus Urinary Tract Infection | indication | ||
| Synergy for Enterococcal Infections | indication | ||
| H. Influenzae Meningitis | indication | ||
| Pulmonary Mycobacterium avium complex infection | off-label use | 186342000 | |
| Hypocalcemia | contraindication | 5291005 | |
| Parkinsonism | contraindication | 32798002 | |
| Dehydration | contraindication | 34095006 | |
| Tinnitus | contraindication | 60862001 | |
| Kidney disease | contraindication | 90708001 | DOID:557 |
| Myasthenia gravis | contraindication | 91637004 | DOID:437 |
| Pregnancy, function | contraindication | 289908002 | |
| Vertigo | contraindication | 399153001 | |
| Inner Ear Disturbance | contraindication | ||
| Disorder of the 8th Cranial Nerve | contraindication | ||
| Infant Botulism | contraindication |
🐶 Veterinary Drug Use
| Species | Use | Relation |
|---|---|---|
| Cattle | Bacterial enteritis caused by Escherichia coli | Indication |
| Cattle | Bacterial enteritis caused by Salmonella spp | Indication |
| Chickens | Nonspecific infectious enteritis caused by bacteria | Indication |
| Swine | Bacterial enteritis caused by Escherichia coli | Indication |
| Swine | Bacterial enteritis caused by Salmonella spp | Indication |
🐶 Veterinary products
| Product | Applicant | Ingredients |
|---|---|---|
| Entromycin Powder | Zoetis Inc. | 2 |
| STREP SOL | Huvepharma EOOD | 1 |
| Streptomycin Oral Solution | Huvepharma EOOD | 1 |
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 12.43 | acidic |
| pKa2 | 12.62 | acidic |
| pKa3 | 13.36 | acidic |
| pKa4 | 13.79 | acidic |
| pKa5 | 11.91 | Basic |
| pKa6 | 11.21 | Basic |
| pKa7 | 6.49 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| 30S ribosomal protein S12 | Ribosomal protein | WOMBAT-PK |
External reference:
| ID | Source |
|---|---|
| 4019933 | VUID |
| N0000148018 | NUI |
| D01350 | KEGG_DRUG |
| 3810-74-0 | SECONDARY_CAS_RN |
| 4017475 | VANDF |
| 4019933 | VANDF |
| C0038425 | UMLSCUI |
| CHEBI:17076 | CHEBI |
| SRY | PDB_CHEM_ID |
| CHEMBL372795 | ChEMBL_ID |
| CHEMBL3184791 | ChEMBL_ID |
| D013307 | MESH_DESCRIPTOR_UI |
| DB01082 | DRUGBANK_ID |
| 10923 | IUPHAR_LIGAND_ID |
| 3685 | INN_ID |
| Y45QSO73OB | UNII |
| 19649 | PUBCHEM_CID |
| 10109 | RXNORM |
| 1794 | MMSL |
| 5514 | MMSL |
| d00159 | MMSL |
| 002770 | NDDF |
| 004895 | NDDF |
| 387223008 | SNOMEDCT_US |
| 40877002 | SNOMEDCT_US |
| 73246001 | SNOMEDCT_US |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Streptomycin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 39822-0706 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 1 g | INTRAMUSCULAR | ANDA | 19 sections |